Titre:
  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Auteur:Azambuja, Evandro; Abdel Azim, Hatem Hamdy; Holmes, Andrew A.P.; Holmes, Eileen; Piccart-Gebhart, Martine; Di Cosimo, Serena; Swaby, Ramona R.F.; Untch, Michael; Jackisch, Christian; Lang, Istvan; Smith, Ian; Boyle, Frances; Xu, Binghe; Barrios, Carlos; Perez, Edith A; Kim, Sung-Bae; Kuemmel, Sherko; Huang, Chiun Sheng; Vuylsteke, Peter; Hsieh, Ruey Kuen; Gorbunova, Vera; Eniu, Alexandru; Dreosti, Lydia; Tavartkiladze, Natalia; Gelber, Richard; Eidtmann, Holger; Baselga, José
Informations sur la publication:Lancet oncology, 15, 10, page (1137-1146)
Statut de publication:Publié, 2014
Sujet CREF:Cancérologie
MeSH keywords:Administration, Oral
Adult
Aged
Antibodies, Monoclonal, Humanized -- adverse effects -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology
Chemotherapy, Adjuvant
Confidence Intervals
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Infusions, Intravenous
Maximum Tolerated Dose
Middle Aged
Neoadjuvant Therapy
Neoplasm Invasiveness -- pathology
Neoplasm Staging
Quinazolines -- adverse effects -- therapeutic use
Receptor, ErbB-2 -- metabolism
Survival Analysis
Treatment Outcome
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1470-2045
info:doi/10.1016/S1470-2045(14)70320-1
info:pii/S1470204514703201
info:scp/84908602324
info:pmid/25130998